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Arginine vasopression (AVP, secreted from hypo-
thalamus, is a multifunctional neurotransmitter that plays 
an important role in water homeostasis [1]. Diabetes 
insipidus (DI) is a metabolic disorder which is caused 
by disturbance in either AVP secretion or function. It is 
characterized with large quantities of urine output with 
low density (> 50 ml/kg, osmolarity < 300 mosmol/L) [2]. 
Granulomatous diseases (i. e. tuberculosis, histiocytosis 
and neurosarcoidosis), hematological malignancies 
(i. e. leukemia and lymphoma) and solid tumors such as 
breast cancer may cause primary central DI. Pituitary me-
tastasis in cancer patients is rare, Most of the reported DI is 
caused in patients with either lung or breast cancers [3]. 
A 62-year old metastatic breast cancer woman was 
admitted to the hospital with serious nausea, vomiting, 
polyuria and polydipsia after 4 months of follow-up period 
without any medication. She had a local recurrence of inva-
sive ductal carcinoma after a 17 year of remission period. 
The patient had been followed for an additional 9 years 
without any local or distant metastasis. Four years ago, 
she developed a lobular carcinoma in contra lateral breast, 
which was surgically removed. Three years later she had 
local and distant metastasis. Distant metastases were in 
skeletal system with multiple involvement, and in ovaries. 
Later liver and lung metastases have also recurred.
The patient’s vomiting was unrelated with foods and 
not projectile. She had no drug history. On examination, 
her performance status was 2 (ECOG), and the rest of 
the physical examination was normal. Despite vomiting, 
the patient had no signs or symptoms of dehydration 
vomiting and, no remarkable finding on neurological 
and otorhinolaryngologic examination except pres-
byacusia. Laboratory tests on admission were as follows: 
creatinine: 1.09 mg/dl (Normal:0.5–0.9 mg/dl), sodium: 
144 mmol/L (normal: 136–146 mmmol/L), potassium: 
3.45 mmol/L (3.5–5.1 mmol/L), calcium: 9.44 mg/dl 
(normal: 8.6–10.2 mg/dl), albumin: 3.5 g/dl (normal: 3.5–
5.2 g/dl), lactate dehydrogenase (LDH): 617 U/L (normal: 
240–480 U/L). Upper gastrointestinal endoscopic biopsy 
was compatible with activated chronic atrophic gastritis. 
The CT scan of the brain (BCT) yielded a suspicious area 
in pituatry gland (Fig. 1). On the third day of admission, 
serum sodium levels started rising daily (147–154 U/L). 
She had polyuria during hypernatremia, but no neurologi-
cal findings. Serum osmolarity was in upper normal limit 
[293 mosmol/kg (normal: 275–295 mosmol/kg)]; urine 
osmolarity was 122 mosmol/kg (repeated values were 
324.78 mosmol/kg and 203.3 mosmol/kg; normal range: 
600–850 mosmol/kg)]; urine sodium was 31 mmol/L 
(repeated value was 6 mmol/L]; urine density was 1002 
(repeated values were 1008 ve 1007). The water depriva-
tion teat was in consistent with DI. She had high basal 
serum osmolarity (306 mosmol/kg), low urine osmolarity 
(234 mosmol/kg) and density (1006) whereas high serum 
osmolarity (303 ve 310 mosmol/kg), and both low urine 
osmolarity (263 ve 321 mosmol/kg) and density (1009 ve 
1011) at second-hour and later on water deprivation test. 
On MR imaging of the brain, a 13 x 10 mm lesion including 
cystic component on posterior part of stalk, which was 
considered as metastasis on was noticed (Fig. 2, a, b). 
Prolactin level was high [76.57 ng/ml; normal: 6–30 ng/ml] 
whereas both insulin like growth factor-1 (IGF-1) and was 
growth hormone (GH) levels were low [69.4 ng/ml for 
IGF-1; normal range: 94–269 ng/ml and 0.01 ng/mL for 
GH; normal range: 0.09–3.83]. She was given Arginin/Va-
sopressin (AVP) nasal spray, 20 mcg bid / day and applied 
‘cyber-knife’ (total 1500 cGy) for stalk metastasis. The 
symptoms of polyuria, nausea and vomitting decreased 
on the third day of the treatment, and hypernatremia 
recovered on the fourth day. Fulvestrant (every 28 days, 
250 mg/day, intramuscular) was given after her symptoms 
had improved. She had been applied fulvestrant for five 
months; however, she died because of disease progres-
sion at the sixth month of DI diagnosis. 
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Fig. 1. A suspicious enhancement in pituatry gland was found 
on CT after intravenous contrast injection
a
b
Fig. 2. A lesion including cystic component on posterior part of 
stalk was found on coronal (a) and midsagittal (b) MR sections 
of the cranium after intravenous contrast injection
Metastasis to the pituitary gland is an uncommon 
site of metastasis of cancer. Breast and lung cancer 
are the two most common tumours that spread to the 
pituitary gland. Diabetes insipidus is rare in cancer 
patients. Teears et al. [4], reported that 69,3% of 
88 cancer patients with hypophyseal metastasis had 
posterior pituitary alone or both anterior and posterior 
pituitary metastasis, and 6,8% of them had DI. Pituitary 
MRI is the most useful imaging modality for pituitary 
pathologies [5]. Hypophysis, stalk, cavernous sinuses, 
sphenoid sinus and optic chiasma are well evaluated 
on coronal and sagittal T1-weighted MRI both before 
and after Gadolonium injection [6]. Lesions on MRI may 
be seen as cystic, nodular or stalk thickening. Poullin 
et al., [7] concluded that a patient who had been dia-
gnosed breast cancer 10 years ago had DI secondary 
to pituitary metastasis according to the symptoms, 
such as polydipsia and polyuria, with stalk thickening 
on pituitary MRI. Furthermore, the patient improved 
after AVP application [7]. Hypophyseal, especially stalk, 
pathologies may not be so clear on BCT. Our patient 
was suspected for pituitary metastasis on BCT, but it 
was more definitive on MRI. Radiotherapy is among the 
treatment modalities of pituitary metastasis. However, 
gamma-knife or cyber-knife is also available for the 
patients who had been treated with radiotherapy before. 
Piedra et al. [8] reported that treatment necessity of 
a cancer patient with DI related to stalk metastasis de-
creased after gamma-knife. We also applied cyberknife 
with 15 Gy. In spite of good response to treatment, the 
breast cancer patients with pitiuitary metastasis and 
DI have poor prognosis with a median survival time of 
6 months [9, 10]. The diagnosis of DI should be kept in 
mind in breast cancer patients with symptoms of serious 
nausea, vomiting, polyuria and polydipsia.
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РАК Молочной железы ПРИ неСАХАРноМ ДИАБеТе 
Несахарный диабет (DI) — редкое клиническое состояние, вызываемое инфильтрацией нейрогипофизарной ножки или 
ножки гипофиза у онкологических больных. Описание случая: в исследовании рассмотрен случай выявления DI у 62-летней 
женщины, у которой был выявлен рак молочной железы с наличием метастазов. Она поступила в больницу с симптомами 
тошноты, рвоты, полиурии и полидипсии, хотя не проходила курса химиотерапии. У больной не выявлено дисбаланса 
электролитов, кроме небольшой гипернатриемии. Компьютерная томография мозга показала подозрительную область 
в мозговом придатке. На магнитно-резонансном изображении выявлен метастаз в ножке гипофиза. Обезвоживание также 
соответствовало диагнозу DI. Получен клинический ответ на назальный вазопрессин. Выводы: онкологические больные 
с симптомами тошноты, рвоты, полиурии и полидипсии, не проходящие курса химиотерапии, должны быть обследованы 
не только на предмет метаболических осложнений, таких как гиперкальциемия, но и на возможное наличие метастазов 
в ножке и задней части гипофиза с помощью магнитно-резонансного изображения.
Ключевые слова: рак, несахарный диабет, метастаз в гипофизе.
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